Related references
Note: Only part of the references are listed.Genomic alterations in STK11 can predict clinical outcomes in cervical cancer patients
Sou Hirose et al.
GYNECOLOGIC ONCOLOGY (2020)
Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
Jacob J. Adashek et al.
ONCOLOGIST (2020)
STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort
Simon Papillon-Cavanagh et al.
ESMO OPEN (2020)
Phenotypic and Genomic Determinants of Immunotherapy Response Associated with Squamousness
Aaron M. Goodman et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy
Aaron M. Goodman et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11
Linnea La Fleur et al.
LUNG CANCER (2019)
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
Matthew D. Hellmann et al.
CANCER CELL (2018)
Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors
Aaron M. Goodman et al.
JAMA ONCOLOGY (2018)
Impact of STK11/LKB1 Genomic Alterations on Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC
F. Skoulidis et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Impact of Major Co-Mutations on the Immune Contexture and Response of KRAS-Mutant Lung Adenocarcinoma to Immunotherapy
Ferdinandos Skoulidis et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value
Francesco Facchinetti et al.
LUNG CANCER (2017)
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Aaron M. Goodman et al.
MOLECULAR CANCER THERAPEUTICS (2017)
STK11/LKB1 co-mutations to predict for de novo resistance to PD-1/PD-L1 axis blockade in KRAS-mutant lung adenocarcinoma.
Ferdinandos Skoulidis et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring an STK11 variant
Christine A. Parachoniak et al.
COLD SPRING HARBOR MOLECULAR CASE STUDIES (2017)
Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma
M. B. Schabath et al.
ONCOGENE (2016)
STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment
Shohei Koyama et al.
CANCER RESEARCH (2016)
Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma
Antonio Calles et al.
CLINICAL CANCER RESEARCH (2015)
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities
Ferdinandos Skoulidis et al.
CANCER DISCOVERY (2015)
Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA
Richard B. Lanman et al.
PLOS ONE (2015)
Hereditary predisposition to cancers of the digestive tract, breast, gynecological and gonadal: Focus on the Peutz-Jeghers
Anthony Turpin et al.
BULLETIN DU CANCER (2014)
AMP Is a True Physiological Regulator of AMP-Activated Protein Kinase by Both Allosteric Activation and Enhancing Net Phosphorylation
Graeme J. Gowans et al.
CELL METABOLISM (2013)
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
Garrett M. Frampton et al.
NATURE BIOTECHNOLOGY (2013)
LKB1/STK11 Inactivation Leads to Expansion of a Prometastatic Tumor Subpopulation in Melanoma
Wenjin Liu et al.
CANCER CELL (2012)
LKB1 Regulated Pathways in Lung Cancer Invasion and Metastasis
Adam I. Marcus et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition
C. L. Mahoney et al.
BRITISH JOURNAL OF CANCER (2009)
Somatic LKB1 Mutations Promote Cervical Cancer Progression
Shana N. Wingo et al.
PLOS ONE (2009)
mTOR and HIF-1α-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome
David B. Shackelford et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome
M. Sanchez-Cespedes
ONCOGENE (2007)
Share Paper
